Future studies on targeting PGRN in combination with other immunomodulatory therapeutic strategies are needed to explore its clinical significance in inducing more durable tumor rejection by targeting central immune escape routes in pancreatic cancer. The gene discussed is GRN; the disease is familial pancreatic carcinoma.